Drug intelligence / Profile preview

OBT698

Development stage: Preclinical
Lead developer: Oxford BioTherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

OBT698 is a preclinical-stage immuno-oncology bispecific antibody being developed by Oxford BioTherapeutics for the treatment of solid tumors. It is designed to simultaneously target Programmed death-ligand 1 (PD-L1) and a second, undisclosed target to modulate anti-tumor immune responses. Discovered using the proprietary OGAP-Verify proteomic platform, OBT698 aims to enhance the immune system's ability to recognize and eliminate cancer cells by combining checkpoint inhibition with another immune-modulating mechanism. The asset is currently in the preclinical phase of development.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on OBT698.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBT698.

Explore the full profile